Comprehensive narrative review of real-world COVID-19 vaccines:viewpoints and opportunities  

作　　者：Shelan Liu Min Kang Na Zhao Yali Zhuang Shijian Li Tie Song 

机构地区：[1]Department of Infectious Diseases,Zhejiang Provincial Centre for Disease Control and Prevention,Hangzhou,Zhejiang Province,China [2]Guangdong Provincial Centre for Disease Control and Prevention,Guangzhou,Guangdong Province,China [3]School of Ecology and Environment,Anhui Normal University,Wuhu,Anhui Province,China [4]Department of Public Health,SUNY Old Westbury,New York,USA [5]Guangdong Provincial Centre for Disease Control and Prevention,No.160 QunXian Road,Panyu District,Guangzhou,Guangdong Province 511430,China

出　　处：《Medical Review》2022年第2期169-196,共28页医学评论（英文）

基　　金：This study was done according to the principles and guidelines of the Declaration of Helsinki,and was approved by the Research Ethics Committee of the Zhejiang Provincial Center for Disease Control and Prevention(Grant No.2020-24).

摘　　要：Currently,people all over the world have been affected by coronavirus disease 2019(COVID-19).Fighting against COVID-19 is the top priority for all the countries and nations.The development of a safe and effective COVID-19 vaccine is considered the optimal way of ending the pandemic.Three hundred and 44 vaccines were in development,with 149 undergoing clinical research and 35 authorized for emergency use as to March 15 of 2022.Many studies have shown the effective role of COVID-19 vaccines in preventing SARS-CoV-2 infections as well as serious and fatal COVID-19 cases.However,tough challenges have arisen regarding COVID-19 vaccines,including long-term immunity,emerging COVID-19 variants,and vaccine inequalities.A systematic review was performed of recent COVID-19 vaccine studies,with a focus on vaccine type,efficacy and effectiveness,and protection against SARS-CoV-2 variants,breakthrough infections,safety,deployment and vaccine strategies used in the real-world.Ultimately,there is a need to establish a unified evaluation standard of vaccine effectiveness,monitor vaccine safety and effectiveness,along with the virological characteristics of SARS-CoV-2 variants;and determine the most useful booster schedule.These aspects must be coordinated to ensure timely responses to beneficial or detrimental situations.In the future,global efforts should be directed toward effective and immediate vaccine allocations,improving vaccine coverage,SARS-CoV-2 new variants tracking,and vaccine booster development.

关 键 词：breakthrough infection coronavirus disease 2019 emergency use authorization mass vaccine administration SARS-CoV-2 variants vaccine type 

分 类 号：R18[医药卫生—流行病学]